Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection
November 09, 2016 07:05 ET | Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
November 04, 2015 16:01 ET | TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
October 06, 2015 07:00 ET | Assembly Biosciences, Inc.
—Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— —Assembly Also...
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
August 05, 2015 16:01 ET | TetraLogic Pharmaceuticals
MALVERN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Provides Update on Hepatitis B Clinical Program
July 20, 2015 16:02 ET | TetraLogic Pharmaceuticals
MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small...
OnCore Biopharma, Inc.
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
November 19, 2014 07:00 ET | OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...
OnCore Biopharma, Inc.
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
September 09, 2014 03:00 ET | OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...
OnCore Biopharma, Inc.
OnCore Biopharma Closes Series R Financing
September 05, 2014 07:00 ET | OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015 Former Pharmasset Team...